We recently published a list of Did Jim Cramer Nail All These 9 Stock Predictions?w. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other stocks that Jim Cramer discussed.

During a recent Mad Money episode, Jim Cramer discussed how President Donald Trump’s influence shapes the market’s behavior:

“When you see a grizzly bear in Yellowstone National Park, you call a park ranger because these bears are dangerous… but the grizzlies turn into teddy bears when the rangers come, and you can’t even remember what you were so afraid of…. We can only presume that the president can turn the grizzlies on Wall Street into teddy bears with a stroke of a pen or even just a post on the social media platform he owns. I’ve never ever seen the market bend so readily to the wishes of one man. It’s extraordinary.”

READ ALSO: What Happened After Jim Cramer Talked About These 13 Stocks and Jim Cramer Defended American Superiority and Discussed These 13 Stocks.

Cramer also addressed the tensions between President Trump and Federal Reserve Chairman Jerome Powell. He highlighted how Powell was painted a “major loser” whose removal seemed inevitable in Trump’s eyes. Cramer noted that the President clarified he had no intention of firing Powell, which eased Wall Street’s concerns. When the name-calling between Trump and Powell stopped, Cramer observed that the stock market surged higher as investors were relieved that the possibility of a constitutional crisis was no longer a threat.

“Now, I want to say something here. I think it is actually, it’s beyond belief how easy it is for this one man to tame a bear, even if it’s a bear that he released on us in the first place.”

Cramer also pointed out that the President’s suggestion of a potential deal with China, while vague, was seen as an improvement and contributed to the market’s upward movement. He noted that for those hoping for higher stock prices, Trump’s actions seemed to have worked.

“Bottom line: That’s how powerful Trump has become on Wall Street. On days like today, it’s helpful, but for most of the year, it’s going the other way. Of course, you never know who he’ll target next. We don’t want any of the big CEOs to be trashed. That could hurt. The market doesn’t care if he goes after law firms or colleges, but going after the Central Bank, different story. Right now, Trump owns Wall Street and only he can decide if that’s going to be a good thing or a bad thing. I think it’s time to go all in on good.”

Methodology

For this article, we compiled a list of 9 stocks that were discussed by Jim Cramer during the episode of Mad Money on April 23, 2024. We then calculated their performance from April 23^rd, 2024, market close to April 25^th, 2025, market close. We have also included the hedge fund sentiment for the stocks, which we sourced from Insider Monkey’s Q4 2024 database of over 900 hedge funds. The stocks are listed in the order that Cramer mentioned them.

Please note that this article mentions Jim Cramer’s previous opinions and may not account for any changes to his opinions regarding the stocks that are mentioned. It is primarily an examination of how his previously provided opinions have panned out.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 21

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech integrating AI into drug discovery, was mentioned by a caller seeking Cramer’s take. Cramer clearly considered it a cutting-edge name with long-term potential at the time. Here’s what he replied with:

“I’ve been waiting for someone to bring this stock up. Why? Because when I was at Nvidia for the great GTC conference, they talked about this company endlessly. I think you have a real winner. The stock went up after around the conference and has come right back down. Recursion is for me. [hits buy button]”

Unfortunately, the stock has since dropped by 26.91%, making his call a clear miss.

Nonetheless, Cramer still likes Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), having talked about a potential upcoming catalyst for the stock. Here’s his analysis from April 11:

“Alright, we got some news from the FDA that’s impacting the stock. I don’t normally do small caps, but there’s an FDA announcement, plan to phase out animal testing requirements for monoclonal antibodies. By the way, Regeneron, biggest in that. But what they’re gonna do is you gotta do it AI. And the AI company that has it, I’ve had them on, is Recursion Pharmaceuticals, RxRx, backed by Jensen Huang and NVIDIA. And they’re going to be the winner in how we decide much faster to have drugs approved in this country. It’s the first real deregulation I’ve seen. Congratulations to the people who are trying to deregulate.”

Overall, RXRX ranks 2nd on our list of stocks that Jim Cramer discussed. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RXRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.